Literature DB >> 1673214

Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry.

P J Harrison1, A J Barton, A Najlerahim, B McDonald, R C Pearson.   

Abstract

A 35S-labelled synthetic oligonucleotide directed against part of the mRNA coding for the M1 subtype muscarinic receptor was used for in situ hybridization histochemistry in sections of human temporal cortex. M1 receptor mRNA was found in cell populations throughout the grey matter, especially in pyramidal cells. Quantitative densitometric analysis of autoradiograms was used to compare levels of this mRNA between Alzheimer's disease and controls. A significant (2.7-fold) increase in hybridization signal was found in Alzheimer's disease cases, both in absolute terms and relative to total polyadenylated mRNA as determined by hybridization with an oligodeoxythymidine probe. Elevated levels of muscarinic receptor mRNA may reflect up-regulation of transcription of this gene in response to the cholinergic deficits occurring in the disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673214     DOI: 10.1016/0169-328x(91)90125-h

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  9 in total

Review 1.  Immunohistochemistry of cholinergic receptors.

Authors:  H Schröder
Journal:  Anat Embryol (Berl)       Date:  1992-10

2.  Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.

Authors:  Cassia R Overk; Christian C Felder; Yuan Tu; Doug A Schober; Kelly R Bales; Joanne Wuu; Elliott J Mufson
Journal:  J Chem Neuroanat       Date:  2010-03-27       Impact factor: 3.052

Review 3.  Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease.

Authors:  A I Levey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

Review 4.  Autoradiographical and immunohistochemical analysis of receptor localization in the central nervous system.

Authors:  J G Chabot; S Kar; R Quirion
Journal:  Histochem J       Date:  1996-11

5.  Increased CSF HVA response to arecoline challenge in Alzheimer's disease.

Authors:  N Pomara; M Stanley; P A LeWitt; M Galloway; R Singh; D Deptula
Journal:  J Neural Transm Gen Sect       Date:  1992

6.  The effect of hyperphenylalaninaemia on the muscarinic acetylcholine receptor in the HPH-5 mouse brain.

Authors:  F A Hommes
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

7.  Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Authors:  Elizabeth Scarr; Catriona McLean; Brian Dean
Journal:  J Neural Transm (Vienna)       Date:  2016-09-29       Impact factor: 3.575

Review 8.  Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease.

Authors:  Touqeer Ahmed; Saadia Zahid; Aamra Mahboob; Syeda Mehpara Farhat
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

9.  A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease.

Authors:  Pradeep J Nathan; S Babli Millais; Alex Godwood; Odile Dewit; David M Cross; Janet Liptrot; Bharat Ruparelia; Stephen Paul Jones; Geor Bakker; Paul T Maruff; Gregory A Light; Alastair J H Brown; Malcolm Peter Weir; Miles Congreve; Tim Tasker
Journal:  Alzheimers Dement (N Y)       Date:  2022-02-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.